A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of oral moxifloxacin compared to oral levofloxacin plus
oral metronidazole in uncomplicated pelvic inflammatory disease (PID)
Phase:
Phase 3
Details
Lead Sponsor:
Bayer
Treatments:
Fluoroquinolones Levofloxacin Metronidazole Moxifloxacin Norgestimate, ethinyl estradiol drug combination Ofloxacin